Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Arcus Biosciences, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Pharmaceutical Preparations
No intraday reading yet this session.
Arcus Biosciences, Inc. has 5 disclosed suppliers and 4 disclosed customers. Each one is named in an SEC filing, either Arcus Biosciences, Inc.’s own annual report or the counterparty’s, and carries the sentence that discloses it.
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“If any of our investigational products obtain marketing approval, we expect to continue to use third-party manufacturers and may also use Gilead's internal manufacturing infrastructure for their optioned products, as appropriate, to deliver commercial supply.”
FILING10-K0001724521-26-000009cik 0001724521
“With respect to zimberelimab, we agreed, as part of the WuXi PD-1 Agreement, that WuXi Biologics would be our exclusive manufacturer of zimberelimab drug substance with respect to clinical and commercial supplies until a certain number of years after marketing approval for zimberelimab, subject to certain exceptions.”
FILING10-K0001724521-26-000009cik 0001724521
“In 2020, we and Gilead entered into the Gilead Collaboration Agreement, as amended, under which Gilead obtained an exclusive license to zimberelimab and time-limited exclusive options to all of our then-current and future programs during the collaboration term.”
FILING10-K0001724521-26-000009cik 0001724521
“For each Taiho optioned program, Taiho is obligated to pay to us (i) an option exercise payment for each program that is between $3 million to $15 million, (ii) clinical, regulatory and commercialization milestones of up to $275 million except for casdatifan (the HIF-2α program) for which we may receive up to $317 million, and (iii) royalties on net sales in Taiho's territories ranging from high single digits to mid-teens.”
FILING10-K0001724521-26-000009cik 0001724521
“In exchange, Taiho will make an option exercise payment to us along with milestone payments upon the achievement of clinical, regulatory and commercialization milestones, and, additionally pay royalties on net sales.”
FILING10-K0001724521-26-000009cik 0001724521
“We also have clinical collaboration agreements with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1b/3 study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC.”
FILING10-K0001724521-26-000009cik 0001724521
“We have in-licensed rights to anti-PD-1 and CD39 antibodies from WuXi Biologics, and to domvanalimab from Abmuno.”
FILING10-K0001724521-26-000009cik 0001724521
“In 2024, we obtained a $250 million term loan facility from Hercules.”
FILING10-K0001724521-26-000009cik 0001724521
“Non-operating income, net consists primarily of interest earned on our investments in fixed-income marketable securities, interest expense on the Hercules Agreement, and non-cash interest expense incurred under the effective interest method on our liability for sale of future royalties to BVF Partners L.P. ("BVF").”
FILING10-K0001724521-26-000009cik 0001724521
Watchlist prices, news filtered to it, and its next report on your desk.
RCUS (Arcus Biosciences, Inc.) has 5 disclosed suppliers and 4 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: GILD +0.52%, in healthcare.